Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

FWIW - Momenta's stock climbs on UBS coverage

MNTA) saw its stock rise more than 5 percent on news that UBS AG equity analysts had initiated coverage on the stock. This despite the fact that the Swiss bank issued an initial Neutral rating with a one-year price target of $17.

The Cambridge, Mass.-based biotechnology company, which launched a successful generic version of Sanofi’s (NYSE: SNY) Lovenox last July, has higher price targets from analysts at Los Angeles-based Wedbush Securities, at $29, and at New York investment banks Rodman and Renshaw and Oppenheimer and Co., Inc., both at $32.

Momenta's stock was trading at $16.57 in afternoon trading Friday, up from $15.69 at the previous close.

Read more: Momenta's stock climbs on UBS coverage | Boston Business Journal

http://www.bizjournals.com/boston/news/2011/04/15/momentas-stock-climbs-on-ubs-coverage.html